/PRNewswire/ DiamiR Biosciences, a developer of innovative non-invasive blood-based diagnostic tests for brain health and other diseases, today announced.
Dyadic International (NASDAQ:DYAI – Get Rating) and Cardiff Oncology (NASDAQ:CRDF – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations. Valuation and Earnings This table compares Dyadic International and […]
Cardiff Oncology (NASDAQ:CRDF – Get Rating) and Autolus Therapeutics (NASDAQ:AUTL – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Risk & Volatility Cardiff Oncology has a beta of […]
DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences
News provided by
Share this article
Share this article
MONMOUTH JUNCTION, N.J., March 17, 2021 /PRNewswire/ DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory in New Haven, CT from Interpace Biosciences, Inc. Subject to specific terms and conditions of the agreement being met, it is anticipated that the transaction will close by the end of April, 2021. Financial terms of this transaction have not been disclosed.